Background {#Sec1}
==========

Prevention and management of invasive fungal diseases (IFDs) may be one of the most challenging problems in children suffering from cancer. Despite recent improvements in diagnosis and management of IFDs, we still witness high attributable morbidity and mortality in those with hematological malignancies \[[@CR1], [@CR2]\]. Among various yeast and mold infections in immunocompromised hosts, *Candida* is the most common cause with wide spectrum clinical manifestations ranging from local infection to severe multi-organ involvement \[[@CR3]\]. *Candida* colonization in hematological malignancies could affect final clinical outcome, especially when colonization occurs with a strain that has reduced susceptibility to azole antifungals \[[@CR4], [@CR5]\]. Also, with prolonged colonization during chemotherapy, the possibility of invasive candidiasis increases with the same colonized isolates \[[@CR6]\]. Although *C. albicans* literally is considered as the leading cause of all *Candida* related IFDs, a shift toward *non-albicans* infections has been identified globally \[[@CR7]--[@CR9]\]. Among the various types of *non-albicans* species, there is growing concern about some of them such as *C. glabrata* and *C. parapsilosis* because of varying degrees of *Azole* antifungal resistance \[[@CR3], [@CR10]\]. Changes in colonization may happen during repeated admissions and various risk factors may make children with hematological malignancies prone to new colonization (especially resistance ones), multi-species colonization or changed primary colonization \[[@CR11]\]. Some of these possible risk factors may be broad-spectrum antibiotic therapy, antifungal prophylaxis, *Azole* antifungal misuse, various types of short/long term indwelling catheters, total parenteral nutrition, neutropenia, surgical interventions, changes in chemotherapy intensity due to refractory disease or relapse, younger age at oncologic diagnosis, repeated IFDs during course of treatment and comorbidities such as hyperglycemia \[[@CR11]--[@CR15]\]. Some of these variables are known risk factor for *Candida* colonization while the role of others needs to be determined by further risk studies \[[@CR16]\]. Although attention to these risk factors and application of proper infection prevention strategies for controllable ones (prevention of *Azole* antifungal misuse, implementation of antimicrobial stewardship programs and prevention of unnecessary prolong catheterization) is almost always ineluctable \[[@CR17]\], such changes in *Candida* colonization should be documented primarily in each individual during repeated admissions by frequent sampling from different possible colonization sites. This study seeks to investigate the epidemiology of *Candida* colonization and any possible changes in colonization pattern in children with malignancies as a part of regular local surveillance program in AMOC in Shiraz, Iran. Indeed, the study was conducted in the continuation of the previous research carried out in 2011-2012 by Haddadi et al. \[[@CR18]\] to investigate the epidemiology of candida colonization and its possible changes during recurrent admissions in AMOC.

Methods {#Sec2}
=======

This prospective, observational study was performed during 2016--2017 on the children hospitalized in a referral oncology teaching hospital, Shiraz, Iran. Amir Hospital is an oncology hospital with 54 beds for children and about 5000 admitted children and adolescents under 18 years of age per each year. This study was conducted on the pediatric patients under 18 years who were suffering from hematological malignancies or solid organ tumors. The study procedure was started after filling consent forms by the patients' parents. As an observational study, demographic data were obtained using predesigned questionnaires.

To examine the rate of *Candida* colonization, oral, urine, nasal, and stool samples were collected upon admission in the wards. Only urine and stool samples were collected from those with severe thrombocytopenia or any type of bleeding tendency and oral and nasal samples were withheld in such cases. To observe the changes in colonization pattern during hospitalization, weekly sampling was performed during total course of admission. The *Candida* colonization index (CI), was calculated as the ratio of the number of non-blood body sites colonized by Candida spp. to the total number of body sites cultured. Samples were cultivated on Sabouraud Dextrose Agar Medium (Merck, Germany). The cultivated Sabouraud Dextrose Agar plates were incubated in ambient temperature and then, the species were identified at mycology division of *Professor Alborzi Clinical Microbiology Research Center* (PACMRC). *Candida* spp. were identified by the formation of germ tube and PCR-RFLP (Polymerase Chain Reaction -Restriction Fragment Length Polymorphism) using forward ITSI1 (5′-TTCCGTAGGTGAACCTGCGG-3′) and reverse ITS4 (5′-TCCTCCGCTTATTGATATGC-3′) primers. The products were digested using MspI (\#ER0541) restriction enzyme \[[@CR19]\]. The normal distribution was confirmed by Kolmogorov--Smirnov test and the obtained data were analyzed by independent sample T-test, Chi-square test using SPSS version 21.0 (IBM Corp. IBM SPSS Statistics for Windows, Armonk, NY). The significance level (*P*-value) of all tests was below 0.05 and α = 0.05. Comparison of the proportions between the present study and our recent study in 2011--2012, was done using MedCalc Software bvba, Version 18.9.1.

Results {#Sec3}
=======

Demographics {#Sec4}
------------

After exclusion, 136 pediatric patients younger than 18 years were recruited in the study and totally, 482 samples were collected from different sites (oral/nasal discharges, urine and stool). Among them 82 (59.9%) were male. The average age was calculated 7.1 years-old (6 ± 4.69 SD, 4 and 18, minimum and maximum, respectively). Detailed data about sex and patient's age category are shown in Table [1](#Tab1){ref-type="table"}. As for the primary underlying disease, *Acute Lymphoblastic Leukemia* (ALL) was the most common oncologic diagnosis (41, 30.1%). Close to 85% (115/136) of the patients had history of recurrent admission (Table [1](#Tab1){ref-type="table"}). The colonization rate was greater in the patients with history of recurrent admission (61.7% versus 38.3%). Totally, 39% of patients had long term follow ups. Of special note, among children with long term follow ups, 71.7% were colonized. In this subgroup of patients, repeated admission was found to be correlated with greater chance of *Candida* colonization (*P*-value = 0.014). Common oncological diagnosis and also their colonization status have been shown in Fig. [1](#Fig1){ref-type="fig"}. Table 1Demographic data in colonized and non- colonized children with malignancyColonization statusP. value^a^YesNoCount%Count%GenderFemale3563.6%2036.4%.512Male4758.0%3442.0%Age group≤12 months00.0%3100.0%1--5 years2959.2%2040.8%.088\> 5 years5363.1%3136.9%Neutropenia (ANC \< 1500)Yes4665.7%2434.3%.160No3553.8%3046.2%History of admissionFirst admission1152.4%1047.6%.420Recurrent admission7161.7%4438.3%a. P-value by Fisher's Exact Test Fig. 1*Candida* colonization status in children with different malignancies. Data are shown based on the most common oncologic diagnosis (data presented in number). Difference was not significant (see text for more information)

Samples' characteristics {#Sec5}
------------------------

Four hundred and eighty-two samples were collected from different sites and finally 140 positive samples were analyzed (excluding negative cultures). About 80% of the patients underwent at least two-time sampling (based on weekly sampling protocol) and more than 20% underwent 3 times or more. Among the collected samples, 195 (40%) were from oral cavity, 220 (46%) from nasal discharges, 44 (9%) from urine, and 24 (5%) from stool. There was no significant difference between colonized and non-colonized patients with regard to age category and sex (P-value = 0.088 and 0.593, respectively).

Colonization status {#Sec6}
-------------------

### A. Patient's colonization status {#Sec7}

*Candida* colonization was found in 59.9% (82/136) of the patients. Most children exhibited oral colonization (67.1%). Oral/Rectal colonization (11%) was the second most common type of colonization among the studied children (Table [2](#Tab2){ref-type="table"}). 72% of the children were colonized with *C. albicans*, followed by *C. krusei* (9.8%), *C. kefyr* (7.3%), *C. glabrata* (2.4%) and *C. parapsilosis* (2.4%). Among the studied patients, one had double colonization with *C. kefir* and *C. parapsilosis* and another one with *C. albicans* and *C. tropicalis*. Data regarding distribution of different colonization sites in colonized children are presented in Table [2](#Tab2){ref-type="table"}. Calculated mean Candida CI was 0.311 ± 0.121 \[1:4 (78%), 2:4 (19.5%) and 3:4 (2.4%)\]. Colonization site preferences were analyzed by Chi-Square Tests for age, sex, degree of neutropenia, primary oncologic diagnosis and recurrent versus new admission (Table [3](#Tab3){ref-type="table"}), revealing no significant differences (*p* = 0.531, *p* = 0.304, 0.125, 0.551 and 0.797, respectively). Also, Candida CI was investigated for these variables that revealed no significant differences, either (*p* = 0.650, *p* = 0.246, 0.259, 0.701 and 0.307, respectively). Table 2Distribution of different colonization sites in 82 colonized children with malignancy ^a^FrequencyValid PercentCumulative PercentOral5567.167.1Nasal33.770.7Fecal67.378.0Oral/Nasal67.385.4Oral/Rectal911.096.3Nasal/ Rectal11.297.6Oral/Nasal/ Rectal22.4100.0Total82100.0a. Urinary colonization was not found Table 3Incidence of different *Candida* species in males and females, predefined age groups, neutropenic patients and those with short and long term follow upSpecies typeSexAge group\*NeutropeniaFollow up durationFemaleMale1--5 year\> 5 yearYesNoNoShort termLong termCount%Count%Count%Count%Count%Count%Count%Count%Count%*C. albicans*2365.7%3676.6%2033.9%3966.1%3458.6%2441.4%3152.5%23.4%2644.1%*C. krusei*12.9%510.6%116.7%583.3%466.7%233.3%350.0%116.7%233.3%C. Kefyr12.9%12.1%150.0%150.0%2100.0%00.0%00.0%00.0%2100.0%*C. glabrata*12.9%12.1%2100.0%00.0%00.0%2100.0%00.0%00.0%2100.0%*C. parapsilosis*00.0%24.3%150.0%150.0%150.0%150.0%150.0%00.0%150.0%*C. lusitaniae*12.9%00.0%00.0%1100.0%00.0%1100.0%00.0%00.0%1100.0%C. Albicans/*C. tropicalis*00.0%12.1%00.0%1100.0%00.0%1100.0%1100.0%00.0%00.0%C. Krusei/C. Tropicalis00.0%00.0%00.0%00.0%00.0%00.0%00.0%00.0%00.0%C. Kefyr/C. Parapsilosis00.0%12.1%00.0%1100.0%1100.0%00.0%00.0%1100.0%00.0%Not defined822.9%00.0%450.0%450.0%450.0%450.0%450.0%00.0%450.0%\*Colonization was not found in children younger than 12 months of age in this study

### B. Sample's characteristics {#Sec8}

From 140 positive samples (excluding black yeasts), species type was determined in 130 samples (10 samples were not recognized). Oral cavity was the most common site of colonization (Fig. [2](#Fig2){ref-type="fig"}), followed by nasal cavity and rectum, 98 (75.4%)**,** 12 (9.2%) and 20 (15.4%), respectively (calculated from all positive samples). Of special note, in this study we did not find any urinary candida colonization among the studied children. Regarding sex differences, we did not observe any correlation between colonization status and sex (*P*-value = 0.593). In terms of age distribution, most of colonized children were over 5 years (53, 63.1%) and the rest 1--5 years (29, 59.2%). Although colonization rate was directly correlated with age category (greater in patients \> 5 years), the difference was not significant (*P*-value = 0.088, LR: 0.05). *Candida* colonization status was investigated based on different underlying oncologic diagnoses. ALL and AML were the most common diagnoses in both colonized and non-colonized children without any significant difference (*P*-value = 0.432). No statistically significant relationship was found between *Candida* colonization and the severity of neutropenia during admission (*P*-value = 0.166). Fig. 2Distribution of different *Candida* spp. in oral cavity, nasal cavity and rectum among colonized patients

### *C. candida* species characteristics {#Sec9}

Among the different types of recognized *Candida* species (140 spp.), *C. albicans* was the most common (72%), followed by *C. krusei* (9.8%), *C. kefyr* (7.3%), *C. glabrata* (2.4%) and *C. parapsilosis* (2.4%); data shown in Fig. [3](#Fig3){ref-type="fig"}. Of the studied patients, one had double colonization with *C. kefir* and *C. parapsilosis* and another with *C. albicans* and *C. tropicalis*. A small proportion of the species could not be distinguished phenotypically on culture media and was categorized as "Not defined" (10 samples). Detailed data regarding different *Candida* species in oral and nasal discharges, and stool samples are summarized in Table [4](#Tab4){ref-type="table"}. Fig. 3Different *Candida* spp. which were recognized in colonized patients (among 131 identified samples including black yeast) Table 4The prevalence of colonization with different *Candida* species in oral and nasal discharges, and stool and urine samplesTotal samples (number)Candida speciesNumber of positive samplesPrevalence\
(% of total oral samples)Oral (195)*C. Albicans*8377.6*C. Krusei*43.7*C. Parapsilosis*43.7*C. Glabrata*32.8*C. Kefyr*21.8*C. Tropicalis*21.8Not defined98.4Nasal (220)*C. Albicans*1076.9*C. kefir*17.6*C. famata*17.6Not defined17.6Stool (24)*C. Albicans*1365*C. Krusei*315*C. Kefyr*15*C. Parapsilosis*15*C. Glabrata*15*C. Tropicalis*15Urine (44) \*------\*No colonization was found in urine specimens

### D. Monitoring of colonization pattern during patient's follow ups {#Sec10}

On average, 53 cases were followed for at least 4 weeks (26.87 days ±SD, 39.6). Follow up duration also was categorized in four-time frame as \< 30 days, 30--60 days, 60--90 days and \> 90 days. More than 64% of colonized children were followed for more than 4 weeks (Table [5](#Tab5){ref-type="table"}). Table 5Follow-up time frames in colonized children with malignancyCount%Cumulative PercentFollow-up time frames\> 90 days1426.426.460--90 days1120.747.130--60 days916.964.2\< 30 days1935.8100Total53100

During the study period, 6.1% of monitored cases had changes in their colonization patterns, indicating non-colonization to colonization and vice versa and also change in candida species (Table [6](#Tab6){ref-type="table"}). During repeated sampling, in 2.2% of colonized cases, colonization was not continued (that indicates negative culture on two occasions at least two weeks apart). Table 6Significant changes in colonization status during follow-upFrequencyPercent ^a^Valid Percent ^b^Cumulative Percent"No colonization" to "colonization"107.450.050.0Change to "colonization with other candida species"75.135.085.0"Decolonization" ^c^32.215.0100.0Total2014.7100.0a. From total colonized casesb. Calculated from those in whom colonization change were detectedc. Negative culture on two occasions at least two weeks apart

The association between recurrent admissions and any type of colonization status change was assessed by Chi-Square Tests which revealed a significant correlation (*p* = 0.035).

Discussion {#Sec11}
==========

Without systematic use of antifungal prophylaxis, invasive *Candida* infections account for the most prevalent type of IFDs in onco-hematological centers \[[@CR14], [@CR18], [@CR20]\] and usually is considered as a consequence of primary colonization \[[@CR17]\]. In this study, nearly 60% of all investigated children were colonized with different *Candida* species. Compared to our recent study in 2011--2012 \[[@CR18]\], we found important findings which needs special consideration.

First, compared to the previous study, we found a substantial increase in colonization rate (46.5% versus 59.9%) \[Difference 13.4, 95% CI: 2.39 to 23.91%, *P* = 0.0173\]. In addition to possibly true increases in the incidence of *Candida* colonization, this increase also could be partially due to regular sampling program which was conducted by the main investigator during the study period.

Second, we found that *Candida non-Albicans* colonization rate decreased significantly from 38 to 18.5% (*P* = 0.0003). Although antifungal prophylaxis in onco-hematological patients receiving intensive chemotherapy is encouraged based on logical argument for reducing mucosal colonization and consequently systemic invasive disease, prolonged azole exposure during antifungal prophylaxis also is considered an important risk factor for shifting in epidemiology of candidiasis \[[@CR20], [@CR21]\]. Due to the very low incidence of proven and probable invasive *Candida* infections in AMOC, currently (after October 2015) Azole prophylaxis is not routinely used in pediatric patients with hematological malignancies as a part of antifungal stewardship program (ASP). Along with other reports this strategy may explain such a decrease in *Candida non-Albicans* colonization rate despite a total increase in the incidence of *Candida* colonization and emphasis on the role of ASP in controlling undesired changing in the epidemiology of candidiasis \[[@CR21], [@CR22]\].

Third, similar to our previous report, *C. krusei* was the most prevalent type of *non-Albicans* species in colonized children. As known, *C. krusei* usually is considered as an important Azole-resistant *non-Albicans* colonizer with a high MIC to fluconazole and voriconazole \[[@CR10]\].

Fourth, we found some increase in the prevalence of *C. parapsilosis* and conversely significant decrease in *C. famata* prevalence in this study. *C. parapsilosis* was the second most common *non-Albicans* species in colonized children, just after *C. krusei*, whereas in our previous study *C. glabrata*, *C. tropicalis* and *C. famata* were more prevalent than *C. parapsilosis*. This is of utmost importance because increased resistance to Azoles frequently was seen with *C. parapsilosis* \[[@CR23]\]. Corresponding data regarding common *non-Albicans* species were shown in Table [7](#Tab7){ref-type="table"}. Table 7Colonization characteristics in both studies conducted in AMOC, in children who were colonized with different Candida species2017--20182011--2012 (18)*p*-value ^c^N ^b^%N ^b^%Candida species ^a^C. *Albicans*10681.611762**0.0003**\*C. *Krusei*75.4189.60.2477C. *Parapsilosis*53.984.30.9126C. *Glabrata*43.1147.50.1559C. *Kefyr*43.142.20.8893C. *Tropicalis*32.4115.90.2262C. *Famata*10.8115.9**0.0416**\*Albicans versus non-Albicans Candida speciesAlbicans10681.611762**0.0003**\*Non-Albicans2418.57238**0.0003**\*Colonization siteOral9875.48838.4**\< 0.0001**\*Nasal129.22410.40.8560Rectal2015.47733.6**0.0003**\*Urine004017.4**\< 0.0001**\*a. Very rare species including *C. guilliermondii*, *C. rugosa*, *C. Lusitaniae*, *C. lambica*, and *Rhodotorula spp*. were excluded from 2011 to 2012 studyb. Number of positive samplesc. Chi-square test\*Statistically significant

Comparable to the previous study in AMOC, ALL was found as the most common oncologic diagnosis in children with hematological malignancies. While acute leukemia was the most common diagnosis in different similar studies, the leukemia type may vary, based on different geographic regions \[[@CR6], [@CR16]\]. In contrast to the study by Albert et al. \[[@CR24]\], we did not find any relationship between colonization status or its change with neutropenia. Treatment of newly diagnosed standard risk ALL usually leads to the first successful remission. Excluding a small number of patients with acceptable response to induction chemotherapy, others usually undergo consequent phases of treatment leading to prolonged maintenance treatment phase which is based on the administration of less intensive regimen on an outpatient basis \[[@CR25]\]. There are several causes that lead to repeated admissions for children with hematological malignancies and such children have greater hospitalization rates, (more than 2-folds), compared to the general population \[[@CR26]\]. The possible role of recurrent hospitalization on *Candida* colonization pattern in children with hematological malignancies has not been determined exactly and in this study, we decided to address this issue. More than two-thirds of our studied cases were on maintenance chemotherapy with recurrent admissions. Although *Candida* colonization rate was significantly greater (more than 6:1) in patients with history of recurrent admission, difference was not statistically significant (*p* = 0.420). However, we found that in the subgroup of children with long term follow up, repeated admission was significantly correlated with a higher *Candida* colonization rate. Similar to other reports \[[@CR27]\], oral cavity was the most common *Candida* colonization site both in this study and our previous report in 2014 \[[@CR18]\], but we found some considerable changes in the present study. First, compared to the previous study, the rate of oral colonization significantly increased (75.4% versus 38.4%). Secondly, we did not find any urinary colonization in this study (Table [6](#Tab6){ref-type="table"}). This may be due to successful adherence to AFS (avoidance of unnecessary catheterization, timely removal of unnecessary catheters and last but not least implementation of antimicrobial stewardship program in our center).

Finally, reports on epidemiologic changes in *Candida* colonization during repeated admissions are somewhat lacking in the literature, especially in children with malignancies \[[@CR28]\]. Our study confirmed that repeated hospitalization in children with malignancy (especially those with ALL) has an important role in changing the face of *Candida* colonization. Consistent with the study by Kaben et al. \[[@CR29]\], we observed some changes to *non-Albicans* species during hospitalization (5.1%, Table [5](#Tab5){ref-type="table"}). Despite observed changes in the pattern of candida colonization and also implementation of non-Azole prophylaxis in high-risk patients, it should be noted that no significant changes have occurred to the burden of candidemia. Incidence rates of candidemia were 4.3, 4.1 and 4.5% during 2015, 2016 and 2017, respectively.

Limitations {#Sec12}
-----------

This study has some limitations. We encountered inevitable limitations in regular and timely sampling from all pre-defined sites due to uncontrolled patients' clinical status. Among them we could mention increased bleeding tendency, thrombocytopenia, delay in taking urine and stool samples in young infants.

Conclusion {#Sec13}
==========

Changing face of *Candida* colonization pattern among high-risk colonized children with different types of malignancies may warrant judicious use of Azoles agents and an urgent need for the implementation of ASP to reduce colonization of resistant *Candida* spp.
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